Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan vs irinotecan + bevacizumab in platinum-resistant non-resectable esophagus, cardia or gastric cancer
2012-002321-30Phase 2Completed
- Sponsor
- University Hospital Odense
- Start
- Nov 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in esophageal adenocarcinoma (EAC), gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing irinotecan monotherapy with irinotecan + bevacizumab (2 arms). Primary endpoint: Progression-free survival. Started Nov 2012; status: completed.
02
Drugs
irinotecanbevacizumab
03
Conditions
esophageal adenocarcinoma (EAC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2012-002321-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002321-30.